Sperimentazioni cliniche

A combination of Rituximab and CC-99282 as front-line therapy for older frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma evaluated with a simplified Geriatric Assessment (sGA): a phase II study of the Fondazione Italiana Linfomi (FIL)

A Long-Term Retrospective and Prospective Safety Study of Arsenic Trioxide in Patients with newly diagnosed, Low- to Intermediate-Risk Acute Promyelocytic Leukemia (APL)

A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for nivolumab + relatlimab Fixed-dose Combination Subcutaneous versus nivolumab + relatlimab Fixed-dose Combination Intravenous and nivolumab Subcutaneous versus nivolumab Intravenous in Participants with Melanoma

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

A phase III, randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a CDK4/6 inhibitor, in patients with estrogen receptor-positive, HER2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapyBREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY

A phase IV trial to confirm the efficacy of olaparib in combination with bevacizumab as maintenance frontline treatment of hrd positive ovarian tumours (IOLANTHE)

A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)

A randomized phase II, double-blind, multicenter study evaluating the efficacy and safety of autogene cevumeran plus nivolumab versus nivolumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma

A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)

A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investigator's Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer

A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after preoperative chemoTherapy and radical surgerY: the TRINITY study.

Akynzeo come trattamento antiemetico in pazienti con carcinoma dell'endometrio trattati con chemioterapia combinata taxano - platino. Studio NOEME

Alterazioni del gusto indotte da chemioterapia in pazienti con carcinoma della mammella: studio osservazionale prospettico - TASTE

An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi

An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi

Analisi del ruolo del test Oncotype DX nei pazienti con carcinoma mammario lobulare classico e non classico (POLLON)

ANalisI delle Alterazioni cliniche, radiologiche e Molecolari dei pazienti adulti affetti da tumori primitivi del sistema nervoso centrale, e il loro impatto sulla decisione terapeutica e sull'outcome (studio ANIMA)

Analisi in real practice dell'efficacia, sicurezza e delle possibili interazioni di Sacituzumab Govitecan utilizzato in monoterapia per il trattamento di pazienti adulti affetti da carcinoma mammario triplo-negativo metastatico (mTNBC) o TNBC non resecabile che abbiano ricevuto in precedenza almeno due terapie sistemiche, almeno una delle quali per la malattia avanzata (SMARTEST)

Analisi in Real Practice delle possibili interazioni degli Antibiotici nei pazienti trattati con Immune Checkpoint Inhibitors (Nivolumab, Avelumab, Pembrolizumab, Cemiplimab, Atezolizumab)